Development of an automated end-to-end next generation sequencing assay to detect all classes of genetic variant in a single diagnostic test

开发自动化端到端下一代测序测定，以在单一诊断测试中检测所有类别的遗传变异

• 批准号: 336921
• 负责人: Karsan Aly
• 金额: $ 33.01万
• 依托单位: BC Cancer, part of PHSA (Vancouver)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-10-01 至 2018-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=336921&lang=en
• 关键词: 1101 - Human Health; 5002- Molecular Genetics; 5004- Genome Analysis; 8000- Health Services; Analytical Validation; Bioinformatics; Clinical Cancer Genomics; Clinical Diagnostics; Clinical Utility; Next-Generation Sequencing

Each year more than 190,000 Canadians are diagnosed with cancer and about 77,000 die from the disease. Genetic testing of tumor tissue is required for most types of cancer to help make a diagnosis and to choose treatments. New methods are now being develo

每年，超过190,000名加拿大人被诊断出患有癌症，大约有77,000人死于该疾病。大多数类型的癌症都需要对肿瘤组织进行基因测试，以帮助做出诊断并选择治疗。新方法现在是Develo